Seneschal Advisors’s AbbVie ABBV Stock Holding History

Seneschal Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.7K	Buy	293 +1	+0.3%	+$215	0.05%	73
2026 Q1	$63.5K	Hold	292	–	–	0.05%	80
2025 Q4	$66.7K	Hold	292	–	–	0.05%	75
2025 Q3	$67.6K	Buy	+292	New	+$59.5K	0.05%	75

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Seneschal Advisors's ABBV Position: Q2 2026 in Review

Seneschal Advisors increased its AbbVie (ABBV) stake by 0.34% in Q2 2026, buying an estimated $215 and bringing the position to 293 shares worth $73.7K. The position accounts for 0.05% of the portfolio, ranked #73.

Seneschal Advisors first reported a position in ABBV in Q3 2025 and has held it in 4 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Seneschal Advisors held 293 shares of AbbVie worth $73.7K as of Q2 2026.
Seneschal Advisors bought 1 AbbVie share in Q2 2026, an estimated $215.
AbbVie made up 0.05% of Seneschal Advisors's portfolio in Q2 2026, its #73 holding.
Seneschal Advisors first reported a position in AbbVie in Q3 2025 and has held it in 4 quarters since.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Seneschal Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.